by Medscape
This podcast delivers Dr. John Mandrola’s summary and perspective on top news of the week that cardiologists can’t miss. This podcast is intended for US health professionals only.
Language
🇺🇲
Publishing Since
9/15/2017
Email Addresses
1 available
Phone Numbers
0 available
April 25, 2025
<p>AI and ECGs, novel ways to treat hypertension, combined lipid-lowering therapy after myocardial infarction, PFA and silent stroke, a move toward accountability in AF ablation, and pacing issues in TTVR are the topics John Mandrola, MD, discusses in this week's podcast.</p> <p>This podcast is intended for healthcare professionals only.</p> <p>To read a partial transcript or to comment, visit:</p> <p>https://www.medscape.com/twic</p> <p><strong>I Help with ECGs in the ED</strong></p> <p><strong>AI Shows Promise for Rapid NSTEMI Diagnosis</strong></p> <p> <strong>https://www.medscape.com/viewarticle/ai-shows-promise-rapid-nstemi-diagnosis-2025a10009pw</strong></p> <ul> <li><strong>Buscher et al https://doi.org/10.1093/eurheartj/ehaf254</strong></li> </ul> <p><strong>II</strong> <strong>A Novel way to Treat HTN</strong></p> <p><strong>A Pacemaker to Control BP Gets FDA Breakthrough Designation</strong></p> <p> <strong>https://www.medscape.com/viewarticle/pacemaker-control-bp-gets-fda-breakthrough-designation-2025a10009t3</strong></p> <ul> <li><strong>JAHA paper https://www.ahajournals.org/doi/10.1161/JAHA.120.020492</strong></li> <li><strong>Backbeat https://clinicaltrials.gov/study/NCT06059638</strong></li> </ul> <p><strong>III Type of PFA may matter for Silent Cerebral Lesions</strong></p> <ul> <li><strong>Paper https://www.ahajournals.org/doi/10.1161/CIRCEP.125.013719</strong></li> </ul> <p><strong>IV Accountability coming to US AF ablation</strong></p> <ul> <li><strong>Heart Rhythm Society Releases a Document on Establishing Centers of Excellence for AF ablation --</strong> Press Release https://www.hrsonline.org/news/new-white-paper-on-atrial-fibrillation-centers-of-excellence/</li> </ul> <p><strong>V Pacing in Patients with Undergoing Transcatheter Tricuspid Valve Replacement</strong></p> <ul> <li>Paper https://doi.org/10.1016/j.hrthm.2025.02.004</li> </ul> <p><strong>You may also like:</strong></p> <p>The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington</p> <p>Questions or feedback, please contact [email protected]</p>
April 18, 2025
<p>The FAME 3 trial 5-year results, TAVR at 5 years, pacers after TAVR, and mavacamten not a wonder drug are the topics John Mandrola, MD, discusses in this week’s podcast.</p> <p>This podcast is intended for healthcare professionals only.</p> <p>To read a partial transcript or to comment, visit:</p> <p>https://www.medscape.com/twic</p> <p><strong>I FAME 3 at Five Years</strong></p> <p><strong>Stents as Good as Surgery for Triple-Vessel Disease https://www.medscape.com/viewarticle/noninvasive-stents-good-surgery-triple-vessel-disease-2025a10007l4</strong></p> <ul> <li><strong>Main trial NEJM https://www.nejm.org/doi/full/10.1056/NEJMoa2112299</strong></li> <li><strong>Circulation 3-years https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.123.065770</strong></li> <li><strong>5-year results Lancet 10.1016/S0140-6736(25)00505-7 https://linkinghub.elsevier.com/retrieve/pii/S0140673625005057</strong></li> </ul> <p><strong>II TAVR in Low-Risk Patients at 5 years</strong></p> <p><strong>5-Year TAVR, Surgery Outcomes Similar in Low-Risk Patients</strong></p> <p> <strong>https://www.medscape.com/viewarticle/5-year-tavr-surgery-outcomes-similar-low-risk-patients-2025a10007zl</strong></p> <ul> <li><strong>EVOLUT Low-Risk 5 years</strong> <strong>https://www.jacc.org/doi/10.1016/j.jacc.2025.03.004</strong></li> <li><strong>EVOLUT Editorial – We're Halfway There</strong><br /> <strong>https://www.jacc.org/doi/10.1016/j.jacc.2025.03.428</strong></li> <li><strong>PARTNER 3 Low-Risk</strong> <strong>https://www.nejm.org/doi/full/10.1056/NEJMoa2307447</strong></li> <li><strong>NOTION at 5 years</strong> <strong>https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.118.036606</strong></li> </ul> <p>III <strong>The Matter of Pacemakers After TAVI</strong></p> <ul> <li><strong>JACC IV Study Badertscher https://www.jacc.org/doi/10.1016/j.jcin.2025.03.028</strong></li> <li><strong>Assessing the quality of reporting of harms in randomized controlled trials published in high impact cardiovascular journals</strong></li> <li> </li> </ul> <p><strong>IV Mavacamten Looks to Have Specific Indications</strong></p> <ul> <li>EXPLORER HCM 10.1016/S0140-6736(20)31792-X External Link</li> <li>VALOR HCM https://jamanetwork.com/journals/jamacardiology/fullarticle/2809050</li> <li>BMS Press Release https://news.bms.com/news/details/2025/Bristol-Myers-Squibb-Provides-Update-on-Phase-3-ODYSSEY-HCM-Trial/</li> </ul> <p>FINAL THOUGHTS</p> <ul> <li>PRAGUE 25 https://bmjopen.bmj.com/content/12/6/e056522</li> </ul> <p><strong>You may also like:</strong></p> <p>The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington</p> <p>Questions or feedback, please contact [email protected]</p>
April 11, 2025
<p>The TAP-IT, STRIDE, FreshUP, and SINGLE SHOT CHAMPION trials are discussed by John Mandrola, MD, in this week's podcast.</p> <p>This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic</p> <p><strong>I TAP IT </strong></p> <p><strong>TAP IT trial https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.124.073521</strong></p> <p><strong>II STRIDE</strong></p> <p><strong>LANCET Ref 10.1016/S0140-6736(25)00509-4</strong></p> <p><strong>SUMMIT HF https://www.nejm.org/doi/full/10.1056/NEJMoa2410027</strong></p> <p><strong>III FRESH UP</strong></p> <p><strong>No Need to Restrict Fluids in Stable Heart Failure</strong></p> <p> <strong>https://www.medscape.com/viewarticle/no-need-restrict-fluids-stable-heart-failure-2025a10008bu</strong></p> <p><strong>Nature (Trial) https://www.nature.com/articles/s41591-025-03628-4</strong></p> <p><strong>SODIUM HF https://pubmed.ncbi.nlm.nih.gov/35381194/</strong></p> <p><strong>IV PFA for AF ablation</strong></p> <p><strong>SINGLE SHOT CHAMPION https://www.nejm.org/doi/full/10.1056/NEJMoa2502280</strong></p> <p><strong>ADVENT https://www.nejm.org/doi/full/10.1056/NEJMoa2307291</strong></p> <p><strong>Foy et al https://pmc.ncbi.nlm.nih.gov/articles/PMC11852674/</strong></p> <p><strong>MANIFEST REDO Study https://doi.org/10.1093/europace/euaf012</strong></p> <p><strong>You may also like:</strong></p> <p>The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington</p> <p>Questions or feedback, please contact [email protected]</p>
American College of Cardiology
American College of Cardiology
CardioNerds
JAMA Network
Core IM Team
American College of Physicians
NEJM Group
JAMA Network
JAMA Network
American College of Cardiology
Mayo Clinic
The Clinical Problem Solvers
The Curbsiders Internal Medicine Podcast
AccessMedicine
Adam Thomas & Josh Farkas
Pod Engine is not affiliated with, endorsed by, or officially connected with any of the podcasts displayed on this platform. We operate independently as a podcast discovery and analytics service.
All podcast artwork, thumbnails, and content displayed on this page are the property of their respective owners and are protected by applicable copyright laws. This includes, but is not limited to, podcast cover art, episode artwork, show descriptions, episode titles, transcripts, audio snippets, and any other content originating from the podcast creators or their licensors.
We display this content under fair use principles and/or implied license for the purpose of podcast discovery, information, and commentary. We make no claim of ownership over any podcast content, artwork, or related materials shown on this platform. All trademarks, service marks, and trade names are the property of their respective owners.
While we strive to ensure all content usage is properly authorized, if you are a rights holder and believe your content is being used inappropriately or without proper authorization, please contact us immediately at [email protected] for prompt review and appropriate action, which may include content removal or proper attribution.
By accessing and using this platform, you acknowledge and agree to respect all applicable copyright laws and intellectual property rights of content owners. Any unauthorized reproduction, distribution, or commercial use of the content displayed on this platform is strictly prohibited.